Early- and late anthracycline-induced cardiac dysfunction: echocardiographic characterization and response to heart failure therapy.

ABSTRACT:

Background

Anthracycline-induced cardiac dysfunction (ACD) is a notorious side effect of anticancer treatment. It has been described as a phenomenon of a continuous progressive decline of cardiac function, eventually leading to dilated cardiomyopathy (DCM). This progressive nature suggests that patients with a delayed ACD diagnosis have greater compromise of cardiac function and more adverse remodeling, with a poor response to heart failure (HF) treatment. This study aimed to delineate the impact of a delayed ACD diagnosis on echocardiographic characteristics and response to HF treatment.

Methods and results

From the population of our cardio-oncology outpatient clinic, 92 ACD patients were included in this study (age 51.6 ± 16.2 years, median cumulative anthracycline dose 32

SUBMITTER: Kamphuis JAM 

PROVIDER: S-EPMC7557080 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature